Medpace Holdings Inc (MEDP)vsNatera Inc (NTRA)
MEDP
Medpace Holdings Inc
$454.25
-0.97%
HEALTHCARE · Cap: $13.35B
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Medpace Holdings Inc generates 7% more annual revenue ($2.68B vs $2.50B). MEDP leads profitability with a 17.2% profit margin vs -9.1%. MEDP earns a higher WallStSmart Score of 66/100 (B-).
MEDP
Strong Buy66
out of 100
Grade: B-
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.2%
Fair Value
$282.31
Current Price
$454.25
$171.94 premium
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 77 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.0%
Revenue surging 26.5% year-over-year
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Grey zone — moderate risk
Expensive relative to growth rate
Trading at 21.7x book value
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 20.0%. Revenue growth of 26.5% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : MEDP
The primary concerns for MEDP are P/E Ratio, Altman Z-Score, PEG Ratio.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
MEDP profiles as a growth stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.54 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
MEDP generates stronger free cash flow (145M), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (66/100 vs 31/100), backed by strong 17.2% margins and 26.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?